rs763469132
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 1P and 9B. PM4_SupportingBP6BS1BS2
The NM_030662.4(MAP2K2):c.863_865del(p.Glu288del) variant causes a inframe deletion change. The variant allele was found at a frequency of 0.0000255 in 1,605,892 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000085 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000019 ( 0 hom. )
Consequence
MAP2K2
NM_030662.4 inframe_deletion
NM_030662.4 inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.78
Genes affected
MAP2K2 (HGNC:6842): (mitogen-activated protein kinase kinase 2) The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
PM4
Nonframeshift variant in NON repetitive region in NM_030662.4. Strenght limited to Supporting due to length of the change: 1aa.
BP6
Variant 19-4099254-CCTT-C is Benign according to our data. Variant chr19-4099254-CCTT-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 503543.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=3, Uncertain_significance=3}.
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.0000853 (13/152354) while in subpopulation AMR AF= 0.000653 (10/15310). AF 95% confidence interval is 0.000354. There are 0 homozygotes in gnomad4. There are 8 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High AC in GnomAd4 at 13 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MAP2K2 | NM_030662.4 | c.863_865del | p.Glu288del | inframe_deletion | 7/11 | ENST00000262948.10 | NP_109587.1 | |
MAP2K2 | XM_047439100.1 | c.293_295del | p.Glu98del | inframe_deletion | 5/9 | XP_047295056.1 | ||
MAP2K2 | XM_006722799.3 | c.705+1762_705+1764del | intron_variant | XP_006722862.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MAP2K2 | ENST00000262948.10 | c.863_865del | p.Glu288del | inframe_deletion | 7/11 | 1 | NM_030662.4 | ENSP00000262948 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152236Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
13
AN:
152236
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000475 AC: 11AN: 231466Hom.: 0 AF XY: 0.0000634 AC XY: 8AN XY: 126248
GnomAD3 exomes
AF:
AC:
11
AN:
231466
Hom.:
AF XY:
AC XY:
8
AN XY:
126248
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000193 AC: 28AN: 1453538Hom.: 0 AF XY: 0.0000263 AC XY: 19AN XY: 722548
GnomAD4 exome
AF:
AC:
28
AN:
1453538
Hom.:
AF XY:
AC XY:
19
AN XY:
722548
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000853 AC: 13AN: 152354Hom.: 0 Cov.: 33 AF XY: 0.000107 AC XY: 8AN XY: 74516
GnomAD4 genome
AF:
AC:
13
AN:
152354
Hom.:
Cov.:
33
AF XY:
AC XY:
8
AN XY:
74516
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not specified Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 06, 2018 | Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: GnomAd 19:4099252 CCTT / C: Latino 6/32102; well conserved; Not in ClinVar, Pubmed, Google search or HGMD - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 16, 2017 | Variant summary: The MAP2K2 c.863_865delAAG (p.Glu288del) variant involves deletion of three adjacent nucleotides. One in silico tool predicts a damaging outcome for this variant. This variant was found in 12/227546 control chromosomes at a frequency of 0.0000527, which is approximately 21 times the estimated maximal expected allele frequency of a pathogenic MAP2K2 variant (0.0000025), suggesting this variant is likely a benign polymorphism. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories; nor evaluated for functional impact by in vivo/vitro studies. One internal LCA sample also carried a pathogenic variant in PTPN11 c.172A>G/p.Asn58Asp (scored as DV), further supporting the benign nature of this variant. Taken together, this variant is classified as likely benign. - |
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Apr 22, 2021 | In-frame deletion of 1 amino acids in a non-repeat region; This variant is associated with the following publications: (PMID: 27060149) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 10, 2022 | BP3 - |
RASopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 07, 2024 | This variant, c.863_865del, results in the deletion of 1 amino acid(s) of the MAP2K2 protein (p.Glu288del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs763469132, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with MAP2K2-related conditions. ClinVar contains an entry for this variant (Variation ID: 503543). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 17, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at